ReviewCellular and molecular life sciences : CMLS2011
Generation of MHC class I ligands in the secretory and vesicular pathways.
Review in Cellular and molecular life sciences : CMLS, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 32 citations in OpenAlex.
- Article
- Alternate MHC I Antigen Presentation Pathways Allow CD8+ T-cell Recognition and Killing of Cancer Cells in the Absence of β2M or TAP.Cancer immunology research · 2025Article
- Cross-modality deep learning-based prediction of TAP binding and naturally processed peptide.Immunogenetics · 2018Article
- Alternative Antigen Processing for MHC Class I: Multiple Roads Lead to Rome.Frontiers in immunology · 2015Review
- VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.Human vaccines & immunotherapeutics · 2014Review
- The effect of proteasome inhibition on the generation of the human leukocyte antigen (HLA) peptidome.Molecular & cellular proteomics : MCP · 2013Article
- Article
- The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.Physiological reviews · 2012Review
- A novel category of antigens enabling CTL immunity to tumor escape variants: Cinderella antigens.Cancer immunology, immunotherapy : CII · 2012Review
- Predictions versus high-throughput experiments in T-cell epitope discovery: competition or synergy?Expert review of vaccines · 2012Article
- Multiple viral ligands naturally presented by different class I molecules in transporter antigen processing-deficient vaccinia virus-infected cells.Journal of virology · 2012Article
- Concerted antigen processing of a short viral antigen by human caspase-5 and -10.The Journal of biological chemistry · 2011Article
- Post-proteasomal and proteasome-independent generation of MHC class I ligands.Cellular and molecular life sciences : CMLS · 2011Review
- Providing ligands for MHC class I molecules.Cellular and molecular life sciences : CMLS · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD8(+) T lymphocytes screen the surface of all cells in the body to detect pathogen infection or oncogenic transformation. They recognize peptides derived from cellular proteins displayed at the plasma membrane by major histocompatibility complex (MHC) class I molecules. Peptides are mostly by-products of cytosolic proteolytic enzymes. Peptidic ligands of MHC class I molecules are also generated in the secretory and vesicular pathways. Features of protein substrates, of proteases and of available MHC class I molecules for loading peptides in these compartments shape a singular collection of ligands that also contain different, longer, and lower affinity peptides than ligands produced in the cytosol. Especially in individuals who lack the transporters associated with antigen processing, TAP, and in infected and tumor cells where TAP is blocked, which thus have no supply of peptides derived from the cytosol, MHC class I ligands generated in the secretory and vesicular pathways contribute to shaping the CD8(+) T lymphocyte response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.